Dare Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 23, 2022, and June 24, 2022. Dare Bioscience, Inc. (DARE) convened its annual meeting of stockholders to vote on six proposals regarding corporate governance, executive compensation, and capital structure.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and stockholder voting results.
Material Changes and Voting Results
- Stock Incentive Plan: Stockholders approved the Dare Bioscience, Inc. 2022 Stock Incentive Plan (Proposal 4). Consequently, no further awards will be granted under the 2014 Stock Incentive Plan.
- Board Elections: All three Class II director nominees (William H. Rastetter, Gregory W. Matz, and Robin J. Steele) were elected to three-year terms.
- Accounting Firm: Stockholders ratified the appointment of Mayer Hoffman McCann P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Executive Compensation: Stockholders approved, on an advisory basis, the compensation of named executive officers (Proposal 3).
- Authorized Share Increase (Pending): Proposal 5, to increase authorized common stock from 120,000,000 to 240,000,000 shares, did not receive sufficient votes to pass. Approximately 49.2% of eligible shares voted "FOR" the proposal.
- Meeting Adjournment: The annual meeting was adjourned solely to allow additional time to solicit proxies for Proposal 5. The meeting will reconvene on July 14, 2022, at 9:00 a.m. Pacific Time.
Outlook, Risks, and Contingencies
The primary contingency noted is the reconvening of the annual meeting on July 14, 2022, to vote on the increase of authorized shares. The filing states that proxies previously submitted will be voted on Proposal 5 at the reconvened meeting unless properly revoked. No other risks or unusual items were disclosed in this specific filing.
Investor Verification Checklist
- Verify the outcome of the reconvened annual meeting on July 14, 2022, regarding the increase in authorized shares.
- Review the definitive proxy statement filed on April 29, 2022, for detailed terms of the approved 2022 Stock Incentive Plan.
- Confirm the final vote tally for Proposal 5 once the reconvened meeting concludes.